

Dear colleagues from abroad,

Thank you very much for attending the 64th annual meeting of the Japan Society of Transfusion Medicine and Cell Therapy, which will be held soon in Kyoto.

Official language of the meeting is Japanese, but we will have the following English session and Japanese session with Japanese-English simultaneous interpretation.

1st Day (28th April)

13:10-14:00 Special Invited Lecture (The first venue)

(with English simultaneous interpretation)

“ Present Status of iPS cell Research and its Clinical Application
“ by Prof. Shinya Yamanaka of Kyoto University (Nobel Laureate,
2012)

14:00-14:50 Special Lecture 2 (English session) (The first venue)

“ Updates with CAR and TCR Engineered T Cells for Cancer “ by
Prof. David Barrett of Children’s Hospital of Philadelphia, USA

14:50-16:50 Symposium 4 (with English simultaneous
interpretation) (The first venue)

“ New Development of Immune-Cell Therapeutics “

- 1) “ Clinical Trial using CD19-specific Chimeric Antigen Receptor Engineered T cells in Japan “ (Prof. Kenichi Ohmine of Jichi Medical University)
- 2) “ New Therapeutics against Cancer using T Cell Receptor Gene-engineered T Cells “ (Prof. Shinichi Kageyama of Mie University, School of Medicine)
- 3) “ Immune Cell Therapy for Cancer by $\gamma\delta$ T cells “ (Prof. Kazuhiro Kakimi of Tokyo University)
- 4) “ Development of Novel Therapeutics with Cancer

Antigen-specific Killer T cells using iPS cell Technology” (Prof. Hiroshi Kawamoto of Kyoto University)

2nd Day (29th April)

15:00-17:00 International Symposium (English session,
with Japanese simultaneous interpretation) (sponsored by
Wako Pure Chemical Industries, Ltd) (The Third Venue)
“Asian Collaborative Study on Alloimmunity for Erythrocyte
Antigens “

- IS-1 Introduction for the collaborative study of alloimmunity in
Asia
Akihiro Takeshita Transfusion and Cell Therapy,
Hamamatsu University School of Medicine
- IS-2 The study of Irregular Antibodies for Erythrocyte in Japan
Chiaki Yamada Transfusion and Cell Therapy,
Hamamatsu University School of Medicine
- IS-3 Irregular Antibodies for Erythrocyte in South Korea
Kyou Sup Han Seoul National University Hospital,
Korea
- IS-4 Transfusion Medicine and the Study of Irregular
Antibodies for Erythrocyte in China
Xianguo Xu Blood Center of Zhejiang Province,
Hangzhou Key Laboratory of Blood Safety Research,
Ministry of Health, China
- IS-5 The Study of Irregular Antibodies for Erythrocytes in
Thailand

Parichart Permpikul Department of Transfusion
Medicine, Faculty of Medicine Siriraj Hospital Mahidol
University, Bangkok, Thailand

- IS-6 Irregular antibodies to erythrocytes in Malaysia
Veera S. Nadarajan Department of Pathology, Faculty of
Medicine, University of Malaya. Kuala Lumpur,
Malaysia.

15:40-17:40 Symposium 11(English session, with Japanese simultaneous
interpretation) (sponsored by Cerus Corporation) (The Second
Venue)

“ The INTERCEPT Blood System Realizing cost-efficiencies and
streamlined operations, with significant clinical benefits “

S-11-1 The Current State of Pathogen Inactivation—Looking at
Factors that Influence Adoption

Richard Benjamin Cerus Corporation, Chair

S-11-2 Assessing Cost Implications when Implementing Pathogen
Inactivation Technology

Dawn Ward University of California, Los Angeles

S-11-3 The Hong Kong Blood Transfusion Service HKBTS
Experience with the INTERCEPT Blood System

Albert Lie Hong Kong Blood Transfusion Service